ArticleCell reports2020
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 265 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
265 citing papers in PubMed, 2 syntheses or guidelines pooled it, 450 citations in OpenAlex.
- Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review.Reviews in medical virology · 2021Pooled it
- The Spike of SARS-CoV-2: Uniqueness and Applications.Frontiers in immunology · 2021Pooled it
- Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.Wiener klinische Wochenschrift · 2021Trial
- SARS-CoV-2 vaccination and infection elicit cross-neutralizing responses against clade 3 and 4 sarbecoviruses.Nature communications · 2026Article
- Design of antibody structure-guided epitope vaccinesJournal of virology · 2025Article
- Antibody-dependent enhancement of SARS-CoV-2, the impact of variants and vaccination.Human vaccines & immunotherapeutics · 2025Article
- Challenges in the Immune System: Mesoscale and Mesoregime Complexity.Cancer innovation · 2025Article
- Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity.PLoS pathogens · 2025Article
- Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies.Scientific reports · 2025Article
- The role of the gut microbiota in regulating responses to vaccination: current knowledge and future directions.The FEBS journal · 2025Review
- The Circulating Proteome─Technological Developments, Current Challenges, and Future Trends.Journal of proteome research · 2024Article
- Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans.NPJ vaccines · 2024Article
- Article
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus · 2024Review
- Development of a quantum dot-based lateral flow immunoassay strip for rapid and sensitive detection of SARS-CoV-2 neutralizing antibodies.Scientific reports · 2023Article
- Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses.JCI insight · 2023Article
- Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera.Nature communications · 2023Article
- Article
- Breastmilk from COVID-19 negative lactating mothers shows neutralizing activity against SARS-COV-2.Scientific reports · 2023Article
- Review
205 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
19 authors at 5 institutions in 3 countries.
Funding
Abstract
The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.